Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $24,944.60 in Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Patrick Burnett sold 955 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.12, for a total transaction of $24,944.60. Following the transaction, the insider owned 119,289 shares in the company, valued at $3,115,828.68. The trade was a 0.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Patrick Burnett also recently made the following trade(s):

• On Monday, May 11th, Patrick Burnett sold 222 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $21.05, for a total transaction of $4,673.10.

Arcutis Biotherapeutics Price Performance

ARQT stock opened at $25.29 on Friday. The firm has a 50 day moving average of $26.05 and a 200-day moving average of $24.69. The company has a market cap of $3.16 billion, a price-to-earnings ratio of 120.43 and a beta of 1.49. The company has a current ratio of 2.92, a quick ratio of 2.46 and a debt-to-equity ratio of 0.46. Arcutis Biotherapeutics, Inc. has a 12-month low of $13.69 and a 12-month high of $31.77.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05. Arcutis Biotherapeutics had a return on equity of 15.05% and a net margin of 6.15%.The business had revenue of $129.86 million for the quarter, compared to analysts’ expectations of $118.85 million. As a group, equities analysts expect that Arcutis Biotherapeutics, Inc. will post 0.16 EPS for the current fiscal year.

Key Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Strong second-quarter performance: Arcutis reported adjusted EPS of $0.11, exceeding estimates of $0.06–$0.09 and improving from a $0.13 loss a year earlier. Revenue rose 59% year over year to $129.9 million, beating the $118.9 million consensus estimate. Arcutis Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Raised sales outlook and expanding ZORYVE opportunity: Management increased 2026 net product-sales guidance to $525 million–$540 million. ZORYVE also gained an expanded pediatric plaque-psoriasis approval, while the FDA accepted an application for use in infants with atopic dermatitis. Arcutis Second-Quarter 2026 Financial Results
• Positive Sentiment: Analyst support remains favorable: Needham raised its price target from $36 to $40 and reiterated a Buy rating. HC Wainwright’s 2027 estimates project quarterly EPS rising from $0.08 in the first quarter to $0.48 in the fourth quarter, suggesting expectations for continued earnings growth. Benzinga analyst report
• Neutral Sentiment: Commercial leadership changes: Arcutis announced key changes to its commercial leadership team. The move could support execution, but investors may initially view management transitions as an operational uncertainty. Arcutis Announces Key Commercial Leadership Changes
• Neutral Sentiment: Insider selling was limited and prearranged: Three executives sold a combined 6,560 shares to cover tax withholding on vested equity awards under Rule 10b5-1 plans, reducing the bearish significance of the transactions.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Wall Street Zen upgraded Arcutis Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Guggenheim lifted their price target on Arcutis Biotherapeutics from $35.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday. Weiss Ratings upgraded shares of Arcutis Biotherapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday. Needham & Company LLC increased their price objective on shares of Arcutis Biotherapeutics from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Morgan Stanley raised their target price on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday. Six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $35.57.

Institutional Investors Weigh In On Arcutis Biotherapeutics

A number of large investors have recently bought and sold shares of ARQT. BlackRock Inc. acquired a new position in Arcutis Biotherapeutics in the 2nd quarter valued at about $276,502,000. Suvretta Capital Management LLC boosted its stake in shares of Arcutis Biotherapeutics by 14.2% during the 4th quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company’s stock worth $347,435,000 after purchasing an additional 1,486,000 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Arcutis Biotherapeutics by 1,228.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,166,348 shares of the company’s stock worth $33,872,000 after purchasing an additional 1,078,546 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Arcutis Biotherapeutics during the fourth quarter worth about $26,136,000. Finally, State Street Corp raised its position in shares of Arcutis Biotherapeutics by 18.2% in the fourth quarter. State Street Corp now owns 5,488,301 shares of the company’s stock valued at $159,380,000 after buying an additional 846,986 shares during the last quarter.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.